References
- World Health Organization. Breast Cancer. Geneva: World Health Organization; 2018. Available from: http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en. [Last accessed on 2020 May 06].
- Shaukat U, Ismail M, Mehmood N. Epidemiology, major risk factors and genetic predisposition for breast cancer in the Pakistani population. Asian Pac J Cancer Prev 2013;14:5625-9.
- Fern JL, Cernea A, Enrique J, Garc C. Automatic Classification of Cell Patterns for Triple Negative Breast Cancer Identification. Primitiva Men 2014;1:151-8.
- Zohre M, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer 2019;11:151-64.
- Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol 2015;8:23-31.
- Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008;8:153.
- Ruibal Á, Aguiar P, Del Rio MC, Arias JI, Menéndez-Rodríguez P, Gude F, Herranz M. Histological grade (HG) in invasive ductal carcinomas of the breast of less than 1 cm: Clinical and biological associations during progression from HG1 to HG3. Anticancer Res 2015;35:569-73.
- Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010;103:1137.
- Yu B, Sun X, Shen H, Gao F, Fan Y, Sun Z. Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity. J Exp Clin Cancer Res 2010;29:107.
- Srivastava N, Manvati S, Srivastava A, Pal R, Kalaiarasan P, Chattopadhyay S, et al. miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: A potential for therapeutic intervention. Breast Cancer Res 2011;13:R39.
- Hendry S, Salgado R, Gevaert T, Russell P, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group. Adv Anat Pathol 2017;24:1.
- Eom YH, Kim HS, Lee A, Song BJ, Chae BJ. BCL2 as a subtype-specific prognostic marker for breast cancer. J Breast Cancer 2016;19:252-60.
- Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol 2010;4:15-34.
- Mdzin R, Lau TY, Rohaizak M, Sharifah NA. Inverse correlation between P53 and Bcl-2 expression in breast carcinoma of Malaysian patients. Med Health 2012;7:32-40.
- Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
- Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, et al. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 2006;7:63-3.
- Lee WY, Jin YT, Tzeng CC. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma. Anticancer Res 1996;16:3007-12.